Funding





Immunai Raises $60M to Reprogram Immunity

The funding will fuel the growth of Immunai’s proprietary AI-first single-cell drug discovery platform Immunai, a New York and Tel Aviv based biotech company, announced today $60M in funding, increasing the company’s total funding-to-date to…